期刊
DNA REPAIR
卷 107, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.dnarep.2021.103203
关键词
Wee1 kinase; Cancer; Hematologic malignancies; Lymphoma; Leukemia
资金
- Tabriz University of Medical Sciences [64476]
Hematologic malignancies originate from hematopoietic stem cells and are currently treated with conventional chemotherapy drugs. However, patients with relapsed or refractory diseases have a poor prognosis, necessitating novel therapeutic approaches. Targeting the Wee1 kinase in these malignancies has shown promise as an effective strategy, particularly in enhancing DNA damage repair processes.
Hematologic malignancies include various diseases that develop from hematopoietic stem cells of bone marrow or lymphatic organs. Currently, conventional DNA-damage-based chemotherapy drugs are approved as standard therapeutic regimens for these malignancies. Although many improvements have been made, patients with relapsed or refractory hematological malignancies have a poor prognosis. Therefore, novel and practical ther-apeutic approaches are required for the treatment of these diseases. Interestingly several studies have shown that targeting Wee1 kinase in the Hematological malignancies, including AML, ALL, CML, CLL, DLBCL, BL, MCL, etc., can be an effective therapeutic strategy. It plays an essential role in regulating the cell cycle process by abro-gating the G2-M cell-cycle checkpoint, which provides time for DNA damage repair before mitotic entry. Consistently, Wee1 overexpression is observed in various Hematological malignancies. Also, in healthy normal cells, repairing DNA damages occurs due to G1-S checkpoint function; however, in the cancer cells, which have an impaired G1-S checkpoint, the damaged DNA repair process depends on the G2-M checkpoint function. Thus, Wee1 inhibition could be a promising target in the presence of DNA damage in order to potentiate multiple therapeutic drugs. This review summarized the potentials and challenges of Wee1 inhibition combined with other therapies as a novel effective therapeutic strategy in Hematological malignancies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据